iShares Core MSCI EAFE ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares Core MSCI EAFE ETF trades at $96.2 (market cap $189.19B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 7.5× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| IEFA | RPRX | |
|---|---|---|
Market Cap | $189.19B | $25.27B |
Volume | 8,441,787 | 3,671,183 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $63.96 |
52-Week Low | $85.06 | $35.44 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with a bearish technical signal. The ETF manages $196 billion in assets, focusing on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors but lower recent performance than some peers. Technical indicators show oversold conditions with RSI at 28.63, while moving averages remain bearish with key support at $95.
The outlook remains cautious given bearish technical momentum and competitive pressure from lower-cost alternatives. International diversification benefits are offset by underperformance relative to global and emerging market ETFs. Key risks include currency fluctuations and concentrated U.S. market exposure driving defensive shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →